These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7924100)

  • 1. Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma.
    Sugimura K; Okizuka H; Kaji Y; Ishida T; Iwanari O; Kitao M
    Clin Nucl Med; 1994 Jul; 19(7):600-3. PubMed ID: 7924100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Port visualization before intraperitoneal chemotherapy: scintigraphy or angiography?].
    Brecht-Krauss D; Vogel J; Hepp G
    Rofo; 1991 Jun; 154(6):638-42. PubMed ID: 1648768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal chemotherapy in peritoneal malignancy: impact of intensive system care on practicability.
    Knüsli C; Ruff P; Laffer U; Stoll HR; Obrist R; Weber W; Obrecht JP
    Acta Med Austriaca; 1989; 16(3-4):70-3. PubMed ID: 2692376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
    Molucon-Chabrot C; Isambert N; Benoit L; Zanetta S; Fraisse J; Guilland JC; Royer B; Monin-Baroille P; Flesch M; Fargeot P; Coudert B; Mayer F; Fumoleau P; Chauffert B
    Anticancer Drugs; 2006 Nov; 17(10):1211-7. PubMed ID: 17075321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intraperitoneal chemotherapy through implantable injection port in patients with advanced ovarian (or tubal) carcinoma].
    Ryuko K; Iwanari O; Moriyama M; Moriyama M; Nakayama S; Miyako J; Kitao M
    Gan To Kagaku Ryoho; 1991 Aug; 18(11):2052-7. PubMed ID: 1877848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Report of case who survived more than five years after repeated intraperitoneal chemotherapy with cisplatin and 5-fluorouracil for treatment of macroscopically negative but microscopically positive peritoneal dissemination of gastric cancer].
    Hiratsuka M; Furukawa H; Yasuda T; Murata K; Nakano H; Ohigashi H; Kameyama M; Sasaki Y; Kabuto T; Ishikawa O; Imaoka S
    Gan To Kagaku Ryoho; 1998 Jul; 25(9):1445-8. PubMed ID: 9703850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer.
    Armstrong DK; Walker JL
    J Clin Oncol; 2019 Sep; 37(27):2416-2419. PubMed ID: 31403863
    [No Abstract]   [Full Text] [Related]  

  • 8. Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
    Markman M; Reichman B; Hakes T; Hoskins W; Rubin S; Jones W; Lewis JL
    Acta Med Austriaca; 1989; 16(3-4):65-7. PubMed ID: 2609915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity.
    Markman M; Cleary S; Lucas WE; Howell SB
    J Clin Oncol; 1985 Jul; 3(7):925-31. PubMed ID: 3894586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
    Roviello F; Pinto E; Corso G; Pedrazzani C; Caruso S; Filippeschi M; Petrioli R; Marsili S; Mazzei MA; Marrelli D
    J Surg Oncol; 2010 Nov; 102(6):663-70. PubMed ID: 20721959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
    Nakayama N; Tanabe S; Koizumi W; Higuchi K; Sasaki T; Nakatani K; Shimoda T; Nishimura K; Kobayashi N; Mitomi H; Saigenji K
    Gan To Kagaku Ryoho; 2006 Nov; 33(11):1641-4. PubMed ID: 17108732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity.
    Markman M; Howell SB; Lucas WE; Pfeifle CE; Green MR
    J Clin Oncol; 1984 Dec; 2(12):1321-6. PubMed ID: 6542584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
    Terauchi F; Moritake T; Yamamoto Y; Ogura H
    Int J Clin Oncol; 2002 Dec; 7(6):356-60. PubMed ID: 12494251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of intraperitoneal chemotherapy for peritoneal recurrence of gastric carcinoma].
    Akamo Y; Takeyama H; Hasegawa M; Teranishi F; Manabe T
    Gan To Kagaku Ryoho; 2001 Oct; 28(11):1659-61. PubMed ID: 11708002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
    Gladieff L; Chatelut E; Gaspard MH; Skaf R; de Forni M; Mihura J; Canal P; Bugat R
    Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
    Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
    Arch Gynecol Obstet; 2018 Apr; 297(4):837-846. PubMed ID: 29356953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
    Chang YH; Lu CH; Yen MS; Lee WH; Chang Y; Chang WP; Chuang CM
    Chin J Cancer; 2016 May; 35():45. PubMed ID: 27160669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of myocutaneous adverse side effect due to intra-arterial chemotherapy by intra-arterial (99m)Tc-macroaggregated albumin administration in patients with bone and soft-tissue tumors.
    Taki J; Sumiya H; Higuchi T; Tsuchiya H; Takazawa K; Tomita K; Tonami N
    J Nucl Med; 2002 Nov; 43(11):1452-6. PubMed ID: 12411547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nutritional status, cachexia, and anorexia in women with peritoneal metastasis and intraperitoneal chemotherapy: a longitudinal analysis.
    Hilal Z; Rezniczek GA; Klenke R; Dogan A; Tempfer CB
    J Gynecol Oncol; 2017 Nov; 28(6):e80. PubMed ID: 29027398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.